Gastric Ulcers - Pipeline Review, H2 2016

Gastric Ulcers - Pipeline Review, H2 2016

  • Products Id :- GMDHC8458IDB
  • |
  • Pages: 43
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Gastric Ulcers - Pipeline Review, H2 2016


Global Markets Direct's, 'Gastric Ulcers - Pipeline Review, H2 2016', provides an overview of the Gastric Ulcers pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastric Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the global therapeutic landscape of Gastric Ulcers

- The report reviews pipeline therapeutics for Gastric Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Gastric Ulcers therapeutics and enlists all their major and minor projects

- The report assesses Gastric Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Gastric Ulcers

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Gastric Ulcers

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Gastric Ulcers pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Gastric Ulcers Overview 6

Therapeutics Development 7

Pipeline Products for Gastric Ulcers - Overview 7

Gastric Ulcers - Therapeutics under Development by Companies 8

Gastric Ulcers - Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Gastric Ulcers - Products under Development by Companies 11

Gastric Ulcers - Companies Involved in Therapeutics Development 12

Ache Laboratorios Farmaceuticos S/A 12

Astellas Pharma Inc. 13

ChoDang Pharm Co., Ltd. 14

Kukje Pharmaceutical Industry Co., Ltd. 15

XuanZhu Pharma Co., Ltd. 16

Gastric Ulcers - Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Combination Products 18

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 24

Drug Profiles 25

(ecabet + ranitidine) - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

anaprazole sodium - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

ASP-6537 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

KJ-14001 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

PDI-39 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

PMKS-005 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Small Molecules for Gastric Ulcers - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Gastric Ulcers - Dormant Projects 32

Gastric Ulcers - Discontinued Products 33

Gastric Ulcers - Product Development Milestones 34

Featured News & Press Releases 34

Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies 34

Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck 35

Jan 07, 2010: AstraZeneca Reaches Agreements with Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations 35

Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy 35

Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc. 36

Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium) 37

Jun 01, 2007: AstraZeneca's Prilosec Patents Upheld By Court 37

Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court 38

Aug 08, 2003: Astrazeneca to Seek Triple Damages in Patent Infringement Lawsuit Against Mylan Pharmaceuticals 38

Oct 23, 2001: Prilosec US litigation 39

May 02, 2001: Astrazeneca Receives Six Months' Market Exclusivity for Prilosec 39

May 02, 2001: Court Denies Generic's Application for Summary Judgement on Prilosec Patent 39

Apr 23, 2001: Astrazeneca Files Lawsuit Against Apotex Corporation and Torpharm for Patent Infringement 39

Dec 19, 2000: Astrazeneca Wins Losec Patent Litigation in Canada 40

Oct 20, 2000: Joint FDA Advisory Committee Confirms OTC Prilosec (Omeprazole) Safety and Efficacy 40

Appendix 42

Methodology 42

Coverage 42

Secondary Research 42

Primary Research 42

Expert Panel Validation 42

Contact Us 42

Disclaimer 43

List of Figures

Number of Products under Development for Gastric Ulcers, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Targets, H2 2016 19

Number of Products by Stage and Targets, H2 2016 19

Number of Products by Mechanism of Actions, H2 2016 21

Number of Products by Stage and Mechanism of Actions, H2 2016 21

Number of Products by Stage and Molecule Types, H2 2016 24

List of Tables

Number of Products under Development for Gastric Ulcers, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Gastric Ulcers - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016 12

Gastric Ulcers - Pipeline by Astellas Pharma Inc., H2 2016 13

Gastric Ulcers - Pipeline by ChoDang Pharm Co., Ltd., H2 2016 14

Gastric Ulcers - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H2 2016 15

Gastric Ulcers - Pipeline by XuanZhu Pharma Co., Ltd., H2 2016 16

Assessment by Monotherapy Products, H2 2016 17

Assessment by Combination Products, H2 2016 18

Number of Products by Stage and Target, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 22

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 24

Gastric Ulcers - Dormant Projects, H2 2016 32

Gastric Ulcers - Discontinued Products, H2 2016 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Ache Laboratorios Farmaceuticos S/A

Astellas Pharma Inc.

ChoDang Pharm Co., Ltd.

Kukje Pharmaceutical Industry Co., Ltd.

XuanZhu Pharma Co., Ltd.

Gastric Ulcers Therapeutic Products under Development, Key Players in Gastric Ulcers Therapeutics, Gastric Ulcers Pipeline Overview, Gastric Ulcers Pipeline, Gastric Ulcers Pipeline Assessment

select a license
Single User License
USD 2000 INR 146960
Site License
USD 4000 INR 293920
Corporate User License
USD 6000 INR 440880



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]